{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:15Z","timestamp":1787017035723,"version":"build-2736575974"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Formycon AG","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Biosimilars are helping to reduce the cost burden of treatment and widen patient access to therapies. This multicentre trial compared the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Patients aged \u226550 years with newly diagnosed nAMD and a best-corrected visual acuity (BCVA) between 20\/40 and 20\/200 Snellen equivalent were randomised (1:1) to double-masked treatment with 2\u2009mg FYB203 or EU-approved reference aflibercept by intravitreal injection every 4 weeks for three doses (baseline, weeks 4 and 8) then every 8 weeks up to week 48. The primary efficacy endpoint was the change from baseline in BCVA by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 8 in the study eye. Therapeutic equivalence of FYB203 and reference aflibercept was demonstrated if, depending on the regulatory requirement with respect to the significance level, the two-sided 90.4% and 95.2%\u2009CIs were within the predefined equivalence interval of (\u22123.5 to 3.5) ETDRS letters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 433 patients received treatment with FYB203 (n=215) or reference aflibercept (n=218). Mean improvement in BCVA from baseline to week 8 was 6.6 ETDRS letters with FYB203 and 5.6 ETDRS letters with reference aflibercept, with an estimated mean treatment difference of 1.0 and the two-sided 90.4%\u2009CI (\u22120.3 to 2.2) and 95.2%\u2009CI (\u22120.6 to 2.5) fully contained within the pre-defined equivalence margins, confirming therapeutic equivalence between FYB203 and reference aflibercept. Safety and immunogenicity profiles were similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although conducted during the COVID-19 pandemic in a potentially vulnerable elderly population and affected by geopolitical disruption in Ukraine, mitigation measures minimised the overall impact of these events. FYB203 demonstrated therapeutic equivalence to reference aflibercept in patients with nAMD, supporting similar clinical performance across all approved indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04522167\">NCT04522167<\/jats:ext-link>\n                      ; EudraCT: 2019-003923-39.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002398","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:25:14Z","timestamp":1767687914000},"page":"e002398","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04522167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04522167","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-1550","authenticated-orcid":false,"given":"Sigrid","family":"Balser","sequence":"first","affiliation":[{"name":"Formycon AG, Martinsried, Planegg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Capsius","sequence":"additional","affiliation":[{"name":"Formycon AG, Martinsried, Planegg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Hole","sequence":"additional","affiliation":[{"name":"Formycon AG, Martinsried, Planegg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Papp","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Preissinger","sequence":"additional","affiliation":[{"name":"Formycon AG, Martinsried, Planegg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Rozenknop","sequence":"additional","affiliation":[{"name":"Formycon AG, Martinsried, Planegg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor","family":"Tiko","sequence":"additional","affiliation":[{"name":"Formycon AG, Martinsried, Planegg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026010600250437000_11.1.e002398.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02609-5"},{"key":"2026010600250437000_11.1.e002398.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"2026010600250437000_11.1.e002398.3","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1186\/s12889-024-21047-x","article-title":"Global burden of low vision and blindness due to age-related macular degeneration from 1990 to 2021 and projections for 2050","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Public Health"},{"key":"2026010600250437000_11.1.e002398.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00631-w"},{"key":"2026010600250437000_11.1.e002398.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.07.028"},{"key":"2026010600250437000_11.1.e002398.6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/09286586.2022.2059812","article-title":"A Systematic Review of Clinical Practice Guidelines for Age-related Macular Degeneration","volume":"30","author":"Han","year":"2023","journal-title":"Ophthalmic Epidemiol"},{"key":"2026010600250437000_11.1.e002398.7","first-page":"1260","article-title":"Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis","volume":"27","author":"Almony","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2026010600250437000_11.1.e002398.8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaophthalmol.2024.4401","article-title":"Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US","volume":"142","author":"Paudel","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026010600250437000_11.1.e002398.9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40123-025-01104-3","article-title":"Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review","volume":"14","author":"Hariprasad","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"2026010600250437000_11.1.e002398.10","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-Vascular Endothelial Growth Factor Biosimilars in Ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"2026010600250437000_11.1.e002398.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001205","article-title":"Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment","volume":"8","author":"Hatamnejad","year":"2023","journal-title":"BMJ Open Ophthalmol"},{"key":"2026010600250437000_11.1.e002398.12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.survophthal.2024.03.009","article-title":"Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review","volume":"69","author":"Bressler","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"2026010600250437000_11.1.e002398.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2026010600250437000_11.1.e002398.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2023-001561","article-title":"Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial","volume":"8","author":"Sadda","year":"2023","journal-title":"BMJ Open Ophth"},{"key":"2026010600250437000_11.1.e002398.15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","article-title":"Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial","volume":"141","author":"Woo","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026010600250437000_11.1.e002398.16","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/IAE.0000000000004174","article-title":"Efficacy and Safety of the Proposed Biosimilar Aflibercept, SDZ-AFL, in Patients with Neovascular Age-Related Macular Degeneration: 52-Week Results From the Phase 3 Mylight Study","volume":"44","author":"Bordon","year":"2024","journal-title":"Retina"},{"key":"2026010600250437000_11.1.e002398.17","doi-asserted-by":"crossref","first-page":"14752","DOI":"10.1038\/s41598-024-65815-6","article-title":"Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration","volume":"14","author":"Kang","year":"2024","journal-title":"Sci Rep"},{"key":"2026010600250437000_11.1.e002398.18","unstructured":"US Food and Drug Administration . Neovascular age-related macular degeneration: developing drugs for treatment\u2014guidance for industry. n.d. Available: https:\/\/www.fda.gov\/media\/165606\/download"},{"key":"2026010600250437000_11.1.e002398.19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","article-title":"Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial","volume":"139","author":"Woo","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2026010600250437000_11.1.e002398.20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"2026010600250437000_11.1.e002398.21","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319637"},{"key":"2026010600250437000_11.1.e002398.22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2016.02.046","article-title":"Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials","volume":"123","author":"Kitchens","year":"2016","journal-title":"Ophthalmology"},{"key":"2026010600250437000_11.1.e002398.23","unstructured":"European Medicines Agency . Eylea. Summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf [Accessed 15 Mar 2025]."},{"key":"2026010600250437000_11.1.e002398.24","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaophthalmol.2024.3458","article-title":"Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial","volume":"142","author":"Bressler","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026010600250437000_11.1.e002398.25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.oret.2024.06.013","article-title":"Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study","volume":"8","author":"Wolf","year":"2024","journal-title":"Ophthalmol Retina"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:25:17Z","timestamp":1767687917000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjophth-2025-002398"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002398","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}